The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Diagnosing RT and identifying patients at risk using NGS and molecular cytogenetic analysis
In this video, Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, outlines the gold standard for diagnosing Richter’s transformation (RT) and expresses her hope that her work on clonal relationship status and genetics of RT will deepen molecular characterization of the malignancy and aid in diagnosis. Dr Parry also comments on the potential of next-generation sequencing (NGS) and molecular cytogenetic analysis to identify which patients possess the mutations associated with a high risk of RT. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
